SCHEMBL3528941

SCHEMBL3528941

Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c(F)c3)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.65
FLT3 P36888 8/20 0.65
LCK P06239 6/20 0.65
FLT1 P17948 6/20 0.65
FLT4 P35916 5/20 0.65
ROCK2 O75116 5/20 0.65
MAP4K4 O95819 5/20 0.65
FGFR1 P11362 5/20 0.65
AXL P30530 5/20 0.65
CSNK1A1 P48729 5/20 0.65
CSNK1D P48730 5/20 0.65
CSNK1G2 P78368 5/20 0.65
MAP4K2 Q12851 5/20 0.65
ROCK1 Q13464 5/20 0.65
CAMK2B Q13554 5/20 0.65
NTRK2 Q16620 5/20 0.65
TAOK1 Q7L7X3 5/20 0.65
HIPK4 Q8NE63 5/20 0.65
AURKB Q96GD4 5/20 0.65
MAP4K5 Q9Y4K4 5/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527005 0.89 KDR (0.77) KDRFLT3LCKFLT1FLT4
SCHEMBL3526303 0.89 FLT1 (0.62) KDRFLT3LCKFLT1FLT4
SCHEMBL3526162 0.89 KDR (0.78) KDRFLT3LCKFLT1FLT4
SCHEMBL3526559 0.88 KDR (0.79) KDRFLT3LCKFLT1FLT4
SCHEMBL3530481 0.88 KDR (0.78) KDRFLT3LCKFLT1FLT4
SCHEMBL4469648 0.86 KDR (0.78) KDRFLT3LCKFLT1FLT4
SCHEMBL3528654 0.86 KDR (0.64) KDRFLT3LCKFLT1FLT4
SCHEMBL3526761 0.83 FLT1 (0.75) KDRFLT3LCKFLT1FLT4
SCHEMBL3532482 0.79 KDR (0.76) KDRFLT3LCKFLT1FLT4
SCHEMBL3524840 0.79 KDR (1.00) KDRFLT3LCKFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885LCK 3/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885LCK 3/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885LCK 3/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885LCK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.